A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

Inclusion Criteria: * Have Type 2 Diabetes Mellitus (T2DM) for ≥1 year prior to screening * Treated for ≥90 days prior to screening with multiple daily injection (MDI) therapy * on basal insulin or insulin glargine 100 U/mL \[Basaglar or Lantus\] or insulin glargin 300 U/mL, insulin determir, insulin degludec U-100, or neutral protamine Hagedorn (NPH) insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro 100 U/mL or 200 U/mL, insulin aspart, insulin glulisine, regular insulin, fast-acting insulin aspart), or * premixed analog or human insulin regimens with any basal and bolus insulin * May have been treated with up to 3 oral antihyperglycemic medications (OAMs) including metformin, sodium-glucose cotransporter (SGLT)-2 inhibitor in accordance with local regulations. The dose of all OAMs must have been stable for ≥90 days prior to screening * Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening * Body mass index ≤45.0 kg/m² * Have access to a telephone, or alternative means for close monitoring/communications * Have refrigeration at home or have ready access to refrigeration for storage of insulin therapy * Have a regular wake-sleep schedule (awake-work during the day and sleep during the night) Exclusion Criteria: * Having any other condition (including known drug or alcohol abuse, psychiatric disorder including eating disorder) that precludes the subject from following and completing the protocol * …